← Leaderboards
Richard B. Markham
Johns Hopkins University
$15,441,953
Attributed
$19,773,905
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$19,773,905 · 15
By mechanism
R01$12,242,763 · 5
R21$2,410,868 · 6
T32$2,309,326 · 1
U19$2,211,048 · 1
S10$439,900 · 1
U09$160,000 · 1
Top collaborators
- Petros C Karakousis7 shared
- Peter C Agre5 shared
- Jay H. Bream5 shared
- Isabelle Coppens5 shared
- George Dimopoulos Dimopoulos5 shared
- Rhoel David Ramos Dinglasan5 shared
- Gregory E Glass5 shared
- Diane E Griffin5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jacques Ravel$18,661,935
- Xiao-Fang Yu$15,220,244
- Karen L. Beemon$8,952,439
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCellsResistanceHiv InfectionsIn VitroResearch PersonnelVirusPharmaceutical PreparationsSamplingInterestReportingResponsePlasmidsVirus GeneticsTechnologyHiv-1ViralAnti-Retroviral AgentsWomanCytokineCd4 Positive T LymphocytesDesignRelapseMutation
Grant awards (47)
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$778,923
R01 · FY2024 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$740,856
R01 · FY2023 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$749,043
R01 · FY2022 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$758,696
R01 · FY2021 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters$732,434
R01 · FY2020 · AI
Immunotherapy Targeting MTB Persisters in the DC-impaired Setting of HIV and TB$204,688
R21 · FY2019 · AI
Immunotherapy Targeting MTB Persisters in the DC-impaired Setting of HIV and TB$245,563
R21 · FY2018 · AI
A Novel Vaccine Platform for Preventing Zika Virus Infection$163,750
R21 · FY2018 · AI · contact PI
A Novel Vaccine Platform for Preventing Zika Virus Infection$286,125
R21 · FY2017 · AI · contact PI
Training: Molecular & Cellular Bases of Infectious Diseases$424,613
T32 · FY2014 · AI
Identification of novel anti-HIV inhibitors based on Vif-E3 activity$202,500
R21 · FY2014 · AI · contact PI
Training: Molecular & Cellular Bases of Infectious Diseases$507,302
T32 · FY2013 · AI
Effect of Cocaine and LTR Polymorphism on HIV-1 Pathogenesis$491,484
R01 · FY2013 · DA · contact PI
Use of clonal genotyping to predict resistance development in ART-naive IDU$578,634
R01 · FY2012 · DA · contact PI
Effect of Cocaine and LTR Polymorphism on HIV-1 Pathogenesis$567,462
R01 · FY2012 · DA · contact PI
Training: Molecular & Cellular Bases of Infectious Diseases$499,422
T32 · FY2012 · AI
Use of clonal genotyping to predict resistance development in ART-naive IDU$578,998
R01 · FY2011 · DA · contact PI
Effect of Cocaine and LTR Polymorphism on HIV-1 Pathogenesis$568,973
R01 · FY2011 · DA · contact PI
Training: Molecular & Cellular Bases of Infectious Diseases$450,573
T32 · FY2011 · AI
Use of clonal genotyping to predict resistance development in ART-naive IDU$579,659
R01 · FY2010 · DA · contact PI
Roche 454 Genome Sequencer FLX$439,900
S10 · FY2010 · RR · contact PI
Training: Molecular & Cellular Bases of Infectious Diseases$427,416
T32 · FY2010 · AI
Development of transformed lactobacilli as a microbicide$246,449
R21 · FY2010 · AI · contact PI
Effect of Cocaine and LTR Polymorphism on HIV-1 Pathogenesis$575,603
R01 · FY2009 · DA · contact PI
Use of clonal genotyping to predict resistance development in ART-naive IDU$568,660
R01 · FY2009 · DA · contact PI
Development of a Malaria DNA Vaccine with Enchanced Immunogenicity$205,000
R21 · FY2009 · AI · contact PI
Development of transformed lactobacilli as a microbicide$199,668
R21 · FY2009 · AI · contact PI
Use of clonal genotyping to predict resistance development in ART-naive IDU$568,290
R01 · FY2008 · DA · contact PI
Effect of Cocaine and LTR Polymorphism on HIV-1 Pathogenesis$556,671
R01 · FY2008 · DA · contact PI
Development of a Malaria DNA Vaccine with Enchanced Immunogenicity$246,000
R21 · FY2008 · AI · contact PI
Anti-ICAM-i scFv from lactobacilli as a Microbicide$575,937
U19 · FY2007 · AI · contact PI
Anti-ICAM-i scFv from lactobacilli as a Microbicide$648,424
U19 · FY2006 · AI · contact PI
Anti-ICAM-i scFv from lactobacilli as a Microbicide$514,609
U19 · FY2005 · AI
Anti-ICAM-i scFv from lactobacilli as a Microbicide$472,078
U19 · FY2004 · AI
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$367,875
R01 · FY2004 · DA
Anti-ICAM-1 scFv from Lactobacilli as a Microbicide$197,625
R21 · FY2004 · AI
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$367,875
R01 · FY2003 · DA
Anti-ICAM-1 scFv from Lactobacilli as a Microbicide$213,500
R21 · FY2003 · AI
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$106,275
R01 · FY2003 · DA
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$367,875
R01 · FY2002 · DA
IMPACT OF RECOMBINATION IN HIV-1 ON INTRAHOST EVOLUTION$317,641
R01 · FY2002 · GM
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW$10,000
U09 · FY2002 · AI
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$367,875
R01 · FY2001 · DA
IMPACT OF RECOMBINATION IN HIV-1 ON INTRAHOST EVOLUTION$301,399
R01 · FY2001 · GM
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW$150,000
U09 · FY2001 · AI
DRUG ABUSE AND RESISTANCE TO ANTIRETROVIRAL THERAPY$357,586
R01 · FY2000 · DA
IMPACT OF RECOMBINATION IN HIV-1 ON INTRAHOST EVOLUTION$293,976
R01 · FY2000 · GM